scholarly journals Primary Jejunal Diffuse Large B-Cell Lymphoma with Multiple Skip Ulcers and Perforation Mimicking Crohn's Disease

2012 ◽  
Vol 6 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Shien-Tung Pan
2019 ◽  
Vol 13 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Koichi Sato ◽  
Tomoaki Suga ◽  
Atsuhiro Hirayama ◽  
Seiichi Daikuhara ◽  
Takeshi Uehara ◽  
...  

2020 ◽  
Vol 13 (4) ◽  
pp. e228818 ◽  
Author(s):  
Adam Joseph Hardy ◽  
Ionica Stoica ◽  
David Edward Kearney ◽  
Diarmuid S O'Riordain

A 62-year-old man presented to our institute with diarrhoea and dysuria on a background of subtotal colectomy and end ileostomy and biological therapy for Crohn’s disease. He was diagnosed with urinary tract infection and acute kidney injury (AKI). Renal ultrasound suggested left hydronephrosis, with renal protocol computed tomography (CT) showing a large pelvic mass. Magnetic resonance imaging (MRI) of the pelvis demonstrated a rectal tumour invading the bladder and compressing both ureters. He underwent cystoscopy, flexible sigmoidoscopy and positron emission tomography–CT and was diagnosed with stage IV non-Hodgkin’s diffuse large B-cell lymphoma. He was treated primarily with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin and prednisolone chemotherapy regimen. He had ongoing urosepsis before admission for pelvic exenteration. He underwent cystoprostatectomy, excision of rectal stump and formation of ileal conduit. Histology showed no signs of residual malignancy. One year later, the patient was admitted to the intensive care unit with aspiration pneumonia, urosepsis and AKI. Despite maximal therapy, he developed multiorgan failure and passed away.


2020 ◽  
Vol 8 (12) ◽  
pp. 3062-3065
Author(s):  
Meriam Sabbah ◽  
Fatma Ben Farhat ◽  
Nawel Bellil ◽  
Fatma Khanchel ◽  
Asma Ouakaa ◽  
...  

2015 ◽  
Vol 65 (4) ◽  
pp. 241 ◽  
Author(s):  
Tae Hyoung Koo ◽  
Won Jong Choi ◽  
Seung Hee Han ◽  
Su Young Kim ◽  
Jong Hun Lee

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document